The CIRCUIT randomized clinical trial (RCT) showed a 12.5 percentage point increase in time spent within the pregnancy-specific glucose range (63-140 mg/dL) for pregnant women with type 1 diabetes using closed-loop insulin delivery compared to standard care.
Closed-loop systems demonstrate consistent benefits across pregnancy phases, including labor and postpartum, with additional data supporting safety and reduction in hypoglycemia.
Subgroup analyses highlight greater benefits in women with baseline HbA1c <7.0%, those new to closed-loop, and individuals without higher education, suggesting targeted clinical advantages.
Healthcare provider perspectives emphasize challenges in training and support, underscoring the importance of specialized education and mentorship for effective closed-loop rollout in pregnancy care.
